Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTREME: Xuezhikang vs Atorvastatin in Prediabetes with Dyslipidemia
NCT05238012Phase 4Completed
- Sponsor
- Heart Health Research Center
- Start
- Aug 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Xuezhikang in prediabetes, dyslipidemia, sponsored by Heart Health Research Center. Started Aug 2022; status: completed.
02
Drugs
Xuezhikang
03
Conditions
prediabetesdyslipidemia
Beyond the preview
Go deeper on NCT05238012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238012.